HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting

Stock News2025-10-28

TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.

The company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.

Notably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.

The company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1195241532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 11:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195241532","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.</p>\n<p>The company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.</p>\n<p>Notably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.</p>\n<p>The company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-28 11:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.</p>\n<p>The company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.</p>\n<p>Notably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.</p>\n<p>The company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1195241532","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195241532","pubTimestamp":1761623776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million. The company recently announced that early clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B"},"translate_title":"港股动向|泰克医药-B(02410)午盘前涨近7%公司在ESMO年会上公布多款CDK抑制剂积极临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"09939":1},"content_text":"TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.\nThe company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.\nNotably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.\nThe company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}